Ipamorelin 5mg Lab Grade Research Peptide — ≥98% Purity

Ipamorelin is a pentapeptide mimetic of growth hormone-releasing peptide (GHRP). Its structure is Aib-His-D-2-Nal-D-Phe-Lys-NH2, where Aib is alpha-aminoisobutyric acid and D-2-Nal is D-2-naphthylalanine. These non-natural residues give the peptide metabolic stability and receptor selectivity.

Ipamorelin acts on the ghrelin receptor (GHS-R1a) on somatotrophs in the anterior pituitary. Unlike non-selective secretagogues, it releases growth hormone without significant effects on cortisol, prolactin, aldosterone, or ACTH in research models. This selectivity makes it useful for studying isolated GH pathways.

The D-amino acid at position 4 (D-Phe) and the Aib residue at position 1 both resist enzymatic degradation. The C-terminal amide (-NH2) is required for biological activity. Researchers use Ipamorelin in studies of pituitary function, GH pulse patterns, and metabolic signaling.

• Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2 (5 residues)
• GHRP mimetic selective for GHS-R1a (ghrelin receptor)
• Does not materially affect cortisol, prolactin, or aldosterone in models
• Molecular formula: C38H49N9O5
• Molecular weight: 711.9 g/mol
• HPLC and mass spectrometry verified
• Lyophilized powder — reconstitute with bacteriostatic water
• For laboratory research only. Not for human or animal consumption.

Contents: 5 mg Ipamorelin — lyophilized powder
Verification: HPLC and mass spectrometry
Use restriction: Research use only. Not for consumption.

Published work on ipamorelin includes:

• Growth hormone release and selectivity studies in swine and rats
• Ghrelin-receptor (GHS-R1a) and pituitary signaling
• Phase 2 clinical trials that did not lead to an approved drug

Note: Ipamorelin sold by CoreVionRX is intended strictly for research purposes. It is not intended for human consumption, diagnostic use, or therapeutic application.